by jlohrconsulting | Sep 20, 2025 | Uncategorized
Int J Obstet Anesth. 2025 Aug 8;64:104750. doi: 10.1016/j.ijoa.2025.104750. Online ahead of print. ABSTRACT BACKGROUND: Remimazolam is an ultra-short-acting intravenous benzodiazepine approved for procedural sedation and general anaesthesia. Its favourable...
by jlohrconsulting | Sep 20, 2025 | Uncategorized
Aust N Z J Psychiatry. 2025 Sep 20:48674251374472. doi: 10.1177/00048674251374472. Online ahead of print. ABSTRACT INTRODUCTION: There is mounting evidence for the use of ketamine/esketamine in the treatment of depression. This paper examines how comorbid borderline...
by jlohrconsulting | Sep 20, 2025 | Uncategorized
Assessment. 2025 Sep 20:10731911251364022. doi: 10.1177/10731911251364022. Online ahead of print. ABSTRACT Large language models can transform individuals’ mental health descriptions into scores that correlate with rating scales approaching theoretical upper...
by jlohrconsulting | Sep 20, 2025 | Uncategorized
Addiction. 2025 Sep 20. doi: 10.1111/add.70187. Online ahead of print. ABSTRACT BACKGROUND & AIMS: There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient...
by jlohrconsulting | Sep 20, 2025 | Uncategorized
Neuropsychopharmacol Rep. 2025 Sep;45(3):e70060. doi: 10.1002/npr2.70060. ABSTRACT Dextromethorphan and bupropion in combination are approved to treat major depressive disorders in adults. This case report describes a patient with a history of treatment-resistant...
Recent Comments